R
Respiree
AI platform and FDA-cleared sensors for tracking disease progression across the care continuum
About Respiree
Respiree is a health technology company based in Singapore with a U.S. presence in Houston at the Texas Medical Center Innovation, building clinically validated artificial intelligence to manage disease progression across the healthcare continuum. Its 1Bio platform combines electronic health record data with the company's proprietary, U.S.-patented sensors to measure and track patient deterioration longitudinally, supporting hospitals, remote monitoring programmes and pharmaceutical and research partners in cardio-respiratory and other chronic conditions. Respiree's technology has FDA 510(k) clearance, is CE marked and is cleared by Australia's Therapeutic Goods Administration, and the company operates in the U.S., Australia and Asia-Pacific. It was founded by CEO Dr Gurpreet Singh. In July 2025 Respiree closed an $11.6 million Series A led by We Venture Capital and ClavystBio, with Adaptive Capital Partners, Greenwillow Capital Management, Seeds Capital and One Six 8 Ventures. In September 2026 the company announced that ARKRAY & PARTNERS (the corporate venture arm of Japan's ARKRAY) and Bizedge Capital had joined its Series A syndicate, with the expanded round used to grow its global commercial team and U.S. operations. Sources: GlobeNewswire 23 Jul 2025; GlobeNewswire Sep 2026; respiree.com.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Singapore
- Employees
- 36
- Open positions
- 1
- Dealroom signal
- 51.8/100
- Industry
- Health, Semiconductors
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Biosensors, Sensor Tech, Sensors, Hard Tech
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2025 | $12M | $46M | She1K · Greenwillow Capital Management · ClavystBio · Seeds Capital | ↗ |
| SEEDEquity / VC | Jan 2023 | $3.5M | $14M | Seeds Capital · Greenwillow Capital Management · A*ccelerate Technologies | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Respiree is 770 monthly website visits, down 40.8% over the last three months. Respiree's team grew 89.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Oriza Holdings
She1K- OFOriza Greenwillow Technology Fund
Seeds Capital
Greenwillow Capital Management- ATA*ccelerate Technologies
Series A3 investors entered at this stage
ClavystBio
We Venture Capital
Adaptive Capital Partners
Other known investors2 additional known investors
Purpose Venture Capital
Startup Creasphere
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Respiree on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Respiree’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.